Tilt Biotherapeutics Ltd.

This early-stage trial is testing the safety of a new two-part treatment for advanced non-small cell lung cancer. The treatment combines a modified virus designed to attack tumors with an existing immunotherapy drug. It is for patients whose cancer has continued to grow despite p…

This early-stage study is testing a new combination treatment for advanced melanoma that has not responded to other therapies. It uses a modified virus designed to infect and kill cancer cells, combined with the patient's own tumor-fighting immune cells and a short course of chem…